252 related articles for article (PubMed ID: 28299661)
1. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
Castilla LH; Bushweller JH
Adv Exp Med Biol; 2017; 962():229-244. PubMed ID: 28299661
[TBL] [Abstract][Full Text] [Related]
2. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
Richter LE; Wang Y; Becker ME; Coburn RA; Williams JT; Amador C; Hyde RK
Mol Cancer Res; 2019 Jun; 17(6):1241-1252. PubMed ID: 30814129
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE
Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia with t(16;16) (p13;q22) showing a new CBFB-MYH11 fusion transcript associated with an atypical leukemic blasts morphology.
Albano F; Anelli L; Zagaria A; Coccaro N; Tota G; Impera L; Minervini CF; Cellamare A; Delia M; Minervini A; Casieri P; Specchia G
Hum Pathol; 2014 Mar; 45(3):643-7. PubMed ID: 24342433
[TBL] [Abstract][Full Text] [Related]
5. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.
Kim HG; Kojima K; Swindle CS; Cotta CV; Huo Y; Reddy V; Klug CA
Blood; 2008 Feb; 111(3):1567-74. PubMed ID: 17967943
[TBL] [Abstract][Full Text] [Related]
6. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16).
Markus J; Garin MT; Bies J; Galili N; Raza A; Thirman MJ; Le Beau MM; Rowley JD; Liu PP; Wolff L
Cancer Res; 2007 Feb; 67(3):992-1000. PubMed ID: 17283131
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapies for inv(16) AML.
Surapally S; Tenen DG; Pulikkan JA
Blood; 2021 May; 137(19):2579-2584. PubMed ID: 33821975
[TBL] [Abstract][Full Text] [Related]
8. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.
Illendula A; Pulikkan JA; Zong H; Grembecka J; Xue L; Sen S; Zhou Y; Boulton A; Kuntimaddi A; Gao Y; Rajewski RA; Guzman ML; Castilla LH; Bushweller JH
Science; 2015 Feb; 347(6223):779-84. PubMed ID: 25678665
[TBL] [Abstract][Full Text] [Related]
9. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.
Richter L; Wang Y; Hyde RK
Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261
[TBL] [Abstract][Full Text] [Related]
10. Cbfbeta reduces Cbfbeta-SMMHC-associated acute myeloid leukemia in mice.
Heilman SA; Kuo YH; Goudswaard CS; Valk PJ; Castilla LH
Cancer Res; 2006 Dec; 66(23):11214-8. PubMed ID: 17145866
[TBL] [Abstract][Full Text] [Related]
11. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
Xiaosu Z; Leqing C; Yazhen Q; Yu W; Xiaohui Z; Lanping X; Xiaojun H; Yingjun C
Ann Hematol; 2019 Jan; 98(1):73-81. PubMed ID: 30159599
[TBL] [Abstract][Full Text] [Related]
12. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
[TBL] [Abstract][Full Text] [Related]
13. Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice.
Saida S; Zhen T; Kim E; Yu K; Lopez G; McReynolds LJ; Liu PP
Leukemia; 2020 Mar; 34(3):759-770. PubMed ID: 31624376
[TBL] [Abstract][Full Text] [Related]
14. RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.
Hyde RK; Liu P; Friedman AD
Adv Exp Med Biol; 2017; 962():265-282. PubMed ID: 28299663
[TBL] [Abstract][Full Text] [Related]
15. c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein.
Bernardin F; Yang Y; Civin CI; Friedman AD
Cancer Biol Ther; 2002; 1(5):492-6. PubMed ID: 12496475
[TBL] [Abstract][Full Text] [Related]
16. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
Zhen T; Cao Y; Ren G; Zhao L; Hyde RK; Lopez G; Feng D; Alemu L; Zhao K; Liu PP
Blood; 2020 Nov; 136(21):2373-2385. PubMed ID: 32929473
[TBL] [Abstract][Full Text] [Related]
17. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
18. CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.
Pulikkan JA; Hegde M; Ahmad HM; Belaghzal H; Illendula A; Yu J; O'Hagan K; Ou J; Muller-Tidow C; Wolfe SA; Zhu LJ; Dekker J; Bushweller JH; Castilla LH
Cell; 2018 Jun; 174(1):172-186.e21. PubMed ID: 29958106
[TBL] [Abstract][Full Text] [Related]
19. Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.
Schnittger S; Bacher U; Haferlach C; Kern W; Haferlach T
Leukemia; 2007 Apr; 21(4):725-31. PubMed ID: 17287858
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
Gao J; Santana-Santos L; Fu L; Alvey E; Chen Q; Wolniak K; Xia Z; Aqil B; Behdad A; Ji P; Sukhanova M; Abaza Y; Altman JK; Chen YH; Lu X
Eur J Haematol; 2024 Jun; 112(6):964-974. PubMed ID: 38388794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]